By Chelsea Naso ( June 18, 2018, 4:54 PM EDT) -- An affiliate of Chinese investment firm Citic Capital offered to buy out U.S.-listed China Biologic in a deal that values the plasma-based biopharmaceutical player at $3.65 billion, after building up a stake in the company, according to a Monday filing with the U.S. Securities and Exchange Commission....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.